Vasomotor Symptoms During Menopause May Up Risk for Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
FRIDAY, Nov. 1, 2024 -- Vasomotor symptoms (VMS) during the menopause transition (MT) are associated with an increased risk for type 2 diabetes (T2D), according to a research letter published online Oct. 31 in JAMA Network Open.
Monique M. Hedderson, Ph.D., from Kaiser Permanente in Pleasanton, California, and colleagues examined the associations of frequency and trajectories of VMS with incident T2D over the MT in the Study of Women's Health Across the Nation. A total of 2,761 premenopausal or early perimenopausal women were assessed at up to 13 approximately annual follow-up visits.
At baseline, 28, 10, and 62 percent of women reported VMS on one to five days per two-week period, VMS on six or more days per week, and no VMS, respectively. Overall, 12.2 percent developed diabetes during follow-up. The researchers observed an association for more frequent time-varying VMS with an increased risk for incident diabetes (hazard ratios, 1.45 and 1.30 for frequent and infrequent VMS, respectively, versus no VMS), after adjustment for covariates. There were four trajectories of VMS: consistently low probability of VMS (26 percent), persistently high probability of VMS (31 percent), early onset-initial high probability that decreased over time (25 percent), and late onset-initial low probability that increased over time (19 percent); 0.2 percent of patients had unknown trajectory. Compared with women with consistently low VMS, those with persistently high VMS had an increased risk for diabetes (hazard ratio, 1.50).
"Women with frequent and/or persistent VMS over the MT may represent a high-risk group to target for diabetes prevention," the authors write.
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
Increasing Proportion of U.S. Adults Unaware They Have Hypertension
MONDAY, June 9, 2025 -- From 2013 to 2023, there was an increase in the proportion of U.S. adults who were unaware of having hypertension, according to a research letter published...
Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM
MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.